Infliximab therapy for corticosteroid-resistant ipilimumabinduced colitis

Journal of Gastrointestinal and Liver Diseases

Volumn 24, Issue 3, 2015, Pages 274-

  Beniwal Patel, Poonam ^a   Matkowskyj, Kristina ^b   Caldera, Freddy ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b University of Wisconsin Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB; IPILIMUMAB; PREDNISONE; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; CORTICOSTEROID; MONOCLONAL ANTIBODY;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADULT; ARTICLE; CASE REPORT; COLITIS; COLON MUCOSA; COLONOSCOPY; CORTICOSTEROID RESISTANT IPILIMUMAB INDUCED COLITIS; DIARRHEA; HUMAN; HUMAN TISSUE; INTESTINE PERFORATION; LAMINA PROPRIA; MALE; MELANOMA; MIDDLE AGED; RECTUM HEMORRHAGE; BIOPSY; CHEMICALLY INDUCED; DRUG RESISTANCE; PATHOLOGY; REMISSION; SKIN NEOPLASMS; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BIOPSY; COLITIS; COLONOSCOPY; DRUG RESISTANCE; HUMANS; INFLIXIMAB; MALE; MELANOMA; MIDDLE AGED; REMISSION INDUCTION; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 84941091930     PISSN: 18418724     EISSN: None     Source Type: Journal    
DOI: 10.15403/jgld.2014.1121.243.bwp     Document Type: Article

References (3)

1. Merrill SP, Reynolds P, Kalra A, Biehl J, Vandivier RW, Mueller SW. Early administration of infliximab for severe ipilimumab-related diarrhea in a critically ill patient. Ann Pharmacother 2014; 48: 806-810. doi: 10.1177/1060028014528152
2. Weber JS, Kähler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipiliumab. J Clin Oncol 2012; 30: 2691-2697. doi: 10.1200/JCO.2012.41.6750
3. Johnston RL, Lutzky J, Chodhry A, Barkin JS. Cytotoxic T-lymphocyteassociated antigen 4 antibody-induced colitis and its management with infliximab. Dig Dis Sci 2009; 54: 2538-2540. doi: 10.1007/s10620-008-0641-z